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Neuronal Ceroid Lipofuscinosis (NCL)
Batten diseaseClinicians, basic researchers, representatives from pharma and families from around the world met in Cordoba,
Argentina in October, 2014 to discuss recent research progress at the 14th International Congress on Neuronal
Ceroid Lipofuscinoses (NCLs; Batten disease), a group of clinically overlapping fatal, inherited lysosomal disorders
with primarily neurodegenerative symptoms. This brief review article will provide perspectives on the anticipated
future directions of NCL basic and clinical research as wemove towards improved diagnosis, care and treatment of
NCL patients.
This article is part of a Special Issue entitled: Current Research on the Neuronal Ceroid Lipofuscinoses (Batten
Disease).
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Following the 14th International Congress on Neuronal Ceroid
Lipofuscinoses (NCLs; Batten disease), a series of up-to-date review ar-
ticles have been compiled in this Special Issue. Here, following the Con-
gress, we look forward and make predictions about what lies ahead for
NCL basic and clinical research.
2. Basic and drug discovery research
An impressive collection of lower organism andmammalian disease
models has been developed since the discovery of the ﬁrst NCL genes in
1995 [1,2]. These diseasemodels,most recently summarized in this Spe-
cial Issue, are increasinglywell characterized and are being employed in
both basic research and pre-clinical drug development for NCL. A major
focus of research efforts is the search for the primary protein functions,
which remain unsolved for most of the NCL proteins. Work in lower or-
ganismmodels should contribute further knowledge on the function of
the evolutionarily conservedNCL proteins, complementing ongoing and
new research efforts that utilize higher organism and human cell-based
models. Expanded efforts into delineating the protein interaction
networks for each of the NCL proteins should also shed important
light on their molecular properties and the extent to which NCL protein
interactomes overlap. With advancing technologies in the ﬁeld of
systems biology, such as transcriptomics, metabolomics, lipidomics,esearch on the Neuronal Ceroid
otman).and proteomics, it is anticipated that more systems level approaches
will be applied to the study of NCL disorders. For example, in other neu-
rodegenerative disease areas and in autoimmune disease, metabolo-
mics research is leading to the development of important diagnostic
and disease tracking biomarkers, as well as important insights into dis-
ease mechanisms [3–5]. With the current array of NCL animal models,
which now exist for CLN1-CLN8 and CLN10-CLN12, these methods
could already be applied to the NCLs.
Patient-derived samples are increasingly being used for NCL-focused
research. Expansion of biobanks that include clinical phenotype
data linked to DNA, tissue samples, cell lines (e.g. EBV-transformed
lymphoblastoid cells, ﬁbroblasts), serum, and plasma will be needed
for biomarker development and for genetic modiﬁer studies. The devel-
opment of cellular reprogramming technology nowmakes it possible to
establish collections of NCL patient induced pluripotent stem cell lines
(iPSCs) that can be differentiated into any cell type of interest [6]. The
successful development of iPSCs from CLN1, CLN2, and CLN3 patients
has recently been reported (Uusi-Rauva, 14th International Congress
on the NCLs Abstract Book, Medicina v74, Suppl. II, and [7]). Efforts to
expand the development of a more comprehensive set of NCL patient
iPSCs are anticipated, and the use of these iPSCs for both basic disease
mechanism and drug discovery research will undoubtedly continue
to grow. Moreover, given increasing evidence that there are cell-type
speciﬁc defects inmany of the NCLs and that the interaction of different
cell-types and even organ systems may play an important role, these
reagents will help facilitate more complex disease modeling (e.g. iPSC-
derived cerebral organoids [8]) to complement whole organism studies
using genetic animal models (e.g. mouse, dog, sheep, pig models, up to
date review in this Special Issue), for an improved understanding of the
full impact of the NCL disease process and how to treat it.
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include:
1) What are the primary functions of each of the NCL proteins?
2) What imparts the selective vulnerability of certain cells over
others (e.g. neurons versus hepatocytes, or one neuronal subtype
over another)?
3) What, if any, overlap is there in the function of each of the NCL
proteins?
In addition to these important questions, it is anticipated that the
fully developed cellular disease models, particularly those involving
the human patient-derived cell lines (e.g. iPSCs and their differentiated
derivatives), will greatly facilitate the application of phenotype-based
genetic and pharmacologic modiﬁer screens to identify lead drugs or
target pathways for further development and testing as NCL treatments.
3. Emerging clinical trials: a need for developing good natural history data
While some forms of NCL remain more challenging for researchers
to solve because they involve loss of function of transmembrane pro-
teins that are poorly understood (e.g. CLN3, CLN6, CLN7, CLN8, and
CLN12), there are exciting developments in the treatment of the
enzymatic forms of NCL (CLN1, CLN2, CLN5), which are most amenable
to gene therapy and enzyme replacement approaches. The most
advanced therapies to date target the CLN2 enzyme, TPP1 (tripeptidyl
peptidase I). Strong pre-clinical data utilizing a Tpp1 knockout mouse
model and a naturally occurring dog model [9–13] led to the develop-
ment of clinical trials testing gene transfer [14] (ClinicalTrials.gov
NCT01414985) and enzyme replacement therapy (Biomarin, BMN
190, clinicaltrials.gov NCT01907087 Biomarin). While these trials are
still ongoing, they are groundbreaking in the NCL ﬁeld because they
have led to the establishment of strong international collaborative net-
works that are succeeding to developmuch needed natural history data
and rating scales with across-site consistency for this form of NCL [14]
(Crystal, 14th International Congress on the NCLs Abstract Book,
Medicina v74, Suppl. II, L-5: Schulz et al., 14th International Congress
on the NCLs Abstract Book, Medicina v74, Suppl. II, O-39). This is critical
for the fair and accurate assessment of efﬁcacy in current and future
clinical trials. As candidate treatments for other forms of NCL make
their way into clinical trials, the successful efforts for CLN2 will serve
as an important model. The ﬁrst CLN3 human clinical trial is also
under way (Phase 2 trial of CellCept, ClinicalTrials.gov NCT01399047)
and is aiding in the optimization of an across-site CLN3 rating scale for
future analysis of efﬁcacy [15–17].
4. Improved diagnosis and supportive care
One of the most signiﬁcant advances in the past decade in genetic
disease research is the development of next generation sequencing
technology, which is expected to widely impact the speed and scope
of clinical genetic testing for all inherited disorders. There are neverthe-
less signiﬁcant challenges in the analysis of the vast genetic data gener-
ated and in its interpretation. Continued use of complementary classical
genetic methods is typically needed. Major efforts around the world to
improve this technology and data interpretation are expected to help
facilitate the implementation of next generation sequence analysis
into clinical genetic testing laboratories.
Through collaborative and NCL genetics consortia efforts, the
application of whole exome sequencing has contributed to the expan-
sion of the clinicopathologic and genetic spectrum of the NCLs. From
eight genes in 2010, the list of genes implicated in NCL is now thirteen,
and the phenotypic spectrum of disease arising from a single gene has
considerably broadened. Of note, several of these newer implicated
genes are also involved in rare forms of Parkinsonism [18], Progressive
Myoclonic Epilepsy without lysosomal storage [19], and in the secondmost common form of adult onset dementia, frontotemporal dementia
(FTD) [20], consistent with overlap in disease mechanisms across
these neurodegenerative brain disorders. A more comprehensive sum-
mary of NCL genetics and these recent advances can be found elsewhere
in this Special Issue (‘Genetics of the NCLs’).
It is expected that additional rare NCL genes will be identiﬁed
as there continue to be patients with an unsolved genetic etiology for
their disorder despite full sequence analysis of the known NCL genes.
The collection of large datasets and mutation databases, such as the
NCL mutation database (http://www.ucl.ac.uk/ncl/mutation.shtml),
particularly if they include functional variant information, will continue
to expand and should further inform our understanding of the molecu-
lar basis of the NCL disorders and should greatly facilitate genetic diag-
nosis of NCL patients. The broadening of the pathogenetic spectrum of
the NCLs should also bring together experts from across disciplines,
which will have a positive impact on the breadth of research into the
role of the NCL proteins in maintaining healthy brain function.
Despite major advances in clinical genetics, the diagnosis of NCL
remains a challenge, even in highly developed countries. Improved
awareness and health professional training should be emphasized. Spe-
ciﬁc recommendations from a panel of experts to improve knowledge
on rare diseases, and in particular on the NCLs, can be found in a sepa-
rate chapter in this Special Issue. In addition to ultimately ﬁnding a
treatment that will prevent or delay the degenerative symptoms of
this devastating group of disorders, research that is aimed at better
management of symptoms should also be emphasized. For example,
associated psychiatric disturbances and seizures in some forms of NCL
are challenging to manage. Clinicians often have little information
to make rational choices for treatment of these symptoms because a
mechanistic understanding of them is lacking. These gaps in the NCL
clinical and research arenas are beginning to be addressed and should
be further supported if we hope to have an impact on the lives of NCL
patients and their caregivers.
5. 15th International Congress on NCL
In two years, the international NCL research community will once
again come together to discuss new research ﬁndings and to build
upon old and new research networks. The meeting will be held in
Boston in the fall of 2016.
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